Purpose: The usage of Chatbots as a kind of Artificial Intelligence in medicine is getting to increase in recent years. UpToDate® is another well-known search tool established on evidence-based knowledge and is used daily by doctors worldwide. In this study, we aimed to investigate the usefulness and reliability of ChatGPT compared to UpToDate in Otorhinolaryngology and Head and Neck Surgery (ORL–HNS). Materials and methods: ChatGPT-3.5 and UpToDate were interrogated for the management of 25 common clinical case scenarios (13 males/12 females) recruited from literature considering the daily observation at the Department of Otorhinolaryngology of Ege University Faculty of Medicine. Scientific references for the management were requested for each clinical case. The accuracy of the references in the ChatGPT answers was assessed on a 0–2 scale and the usefulness of the ChatGPT and UpToDate answers was assessed with 1–3 scores by reviewers. UpToDate and ChatGPT 3.5 responses were compared. Results: ChatGPT did not give references in some questions in contrast to UpToDate. Information on the ChatGPT was limited to 2021. UpToDate supported the paper with subheadings, tables, figures, and algorithms. The mean accuracy score of references in ChatGPT answers was 0.25–weak/unrelated. The median (Q1–Q3) was 1.00 (1.25–2.00) for ChatGPT and 2.63 (2.75–3.00) for UpToDate, the difference was statistically significant (p < 0.001). UpToDate was observed more useful and reliable than ChatGPT. Conclusions: ChatGPT has the potential to support the physicians to find out the information but our results suggest that ChatGPT needs to be improved to increase the usefulness and reliability of medical evidence-based knowledge.

Small-cell lung cancer (SCLC) is a highly aggressive tumor with a high metastatic potential, particularly affecting current or former heavy smokers. Treatment typically involves chemotherapy, often combined with radiotherapy, and immunotherapy for extensive disease. Prophylactic cranial irradiation is recommended to reduce brain metastases. Elderly SCLC patients face unique challenges due to frailty and comorbidities, leading to increased risks of treatment-related toxicity and malnutrition. The prognostic nutritional index (PNI), a composite marker of nutritional and immune status, has shown promise in predicting outcomes in various malignancies. However, the optimal treatment approach for very elderly SCLC patients remains unclear, as they are often excluded from clinical trials. This study aimed to evaluate the survival outcomes of SCLC patients aged 75 years or older and their correlation with PNI. Retrospective cohort study. The study retrospectively analyzed data from 71 SCLC patients aged ≥75 years, focusing on age, gender, smoking status, chronic diseases, performance status, clinical stage, treatment modality, and pretreatment PNI. Survival estimates were calculated using the Kaplan-Meier method, and multivariate Cox regression analysis was performed to identify independent predictors of overall survival (OS). The results demonstrated that 26.8% of very elderly SCLC patients received no active treatment, resulting in a significantly shorter median survival time of 1.3 months. In contrast, patients who underwent aggressive treatment, such as palliative chemotherapy or chemotherapy plus radiotherapy, had significantly longer median survival times. Multivariate analysis revealed that receiving chemotherapy plus radiotherapy was associated with a significant survival benefit compared to no treatment. Furthermore, low PNI (≤40) was independently associated with decreased OS. This study highlights the importance of active treatment and nutritional support in improving survival outcomes for very elderly SCLC patients. The findings suggest that low PNI and lack of oncological treatment are associated with worse survival outcomes. Therefore, integrating nutritional assessment, interventions, and appropriate treatment strategies are crucial in managing lung cancer patients. Larger, multicenter studies are needed to validate these findings and explore potential interventions to optimize nutritional status and improve outcomes for elderly patients with SCLC.

Background: The management of early rectal cancer is different from that of colon cancer in terms of radiotherapy (RT) requirements or neoadjuvant treatment. It is not clear how the course of rectal cancer differs from that of the colon in a metastatic setting or how it should be approached differently. This study aimed to evaluate outcomes after combining downsizing chemotherapy (CTx) with rescue surgery. Methods: Eighty-nine patients (57 men and 32 women) diagnosed with metastatic rectal cancer with resectable disease after systemic CTx were included in the study. All patients underwent surgery for the primary mass and metastasis, but none received radiation therapy before or after surgery. Survival curves for overall survival (OS) and progression-free survival (PFS) were generated using the Kaplan-Meier method and compared with the log-rank test for subgroups. Results: The median follow-up time was 28.8 (17.6-39.4) months. During the follow-up, 54 (60.7%) patients died and 78 (87.6%) patients had a PFS event. Cancer relapsed in 72 (80.9%) patients. Median OS was 35.2 (95% CI: 28.5-41.8) months, and median PFS was 17.7 (95% CI: 14.4-21) months. The five-year OS and PFS were 19% and 3.5%, respectively. Male sex (p=0.04) and a better Mandard score (p=0.021) were associated with a longer OS, while obesity was associated with a shorter PFS (p<0.001). Conclusion: Our study is the first to evaluate the effects of metastasectomy after conversion therapy in metastatic rectal cancer independent of colon cancer. As a result of the study, it was seen that the survival after metastasectomy in rectal cancer is worse than the colon cancer data known from previous studies.